Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness
Nora Pencheva,
Mark C. de Gooijer,
Daniel J. Vis,
Lodewyk F.A. Wessels,
Tom Würdinger,
Olaf van Tellingen,
René Bernards
Affiliations
Nora Pencheva
Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
Mark C. de Gooijer
Division of Pharmacology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
Daniel J. Vis
Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
Lodewyk F.A. Wessels
Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
Tom Würdinger
Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands
Olaf van Tellingen
Division of Pharmacology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
René Bernards
Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
Diffuse and uncontrollable brain invasion is a hallmark of glioblastoma (GBM), but its mechanism is understood poorly. We developed a 3D ex vivo organotypic model to study GBM invasion. We demonstrate that invading GBM cells upregulate a network of extracellular matrix (ECM) components, including multiple collagens, whose expression correlates strongly with grade and clinical outcome. We identify interferon regulatory factor 3 (IRF3) as a transcriptional repressor of ECM factors and show that IRF3 acts as a suppressor of GBM invasion. Therapeutic activation of IRF3 by inhibiting casein kinase 2 (CK2)—a negative regulator of IRF3—downregulated the expression of ECM factors and suppressed GBM invasion in ex vivo and in vivo models across a panel of patient-derived GBM cell lines representative of the main molecular GBM subtypes. Our data provide mechanistic insight into the invasive capacity of GBM tumors and identify a potential therapy to inhibit GBM invasion.